3rd Quarter - Amendment

ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP

Firm
Client
Income
—
Expenses
$450,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 18, 2019 $450,000 Replaced
3rd Quarter - Amendment (this page) Oct 20, 2019 $450,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

FDA Patent Settlement legislation Intellectual property and patent issues S. 340, H.R. 965 CREATES Act S. 1209, REMEDY Act S. 1224, H.R. 2374, Stop STALLING Act

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES —
HELEN DWIGHT —
JULIE GARNER —
NATALIE MORRIS —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS)

Bills named: H.R. 965 (116th), H.R. 2374 (116th), S. 340 (116th), S. 1224 (116th), S. 1209 (116th)

Health Issues HCR

Value of Prescription Drugs Drug Pricing Transparency Oncology Care Model Personalized Medicine Diagnostics S. 1895, Lower Health Care Costs Act HR 3 drug pricing bill

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES —
HELEN DWIGHT —
JULIE GARNER —
NATALIE MORRIS —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS)

Bills named: S. 1895 (116th), H.R. 3 (116th)

Medicare/Medicaid MMM

Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D; Rebate Rule Medicare Part B coverage and reimbursement Changes to the Medicaid Drug Rebate Program (AMP Cap) Medicare Part B Intl. Pricing Index ANPRM 14 Day Rule End State Renal Disease PPS Senate Finance drug pricing package HR 3 drug pricing bill

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES .
HELEN DWIGHT —
JULIE GARNER —
NATALIE MORRIS —

Contacted: Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 3 (116th)

Pharmacy PHA

Medicare Part D coverage and reimbursement Value of Prescription Drugs Prescription Drug Importation Innovative Payment Models Price Transparency Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act S. 64, H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES —
HELEN DWIGHT —
JULIE GARNER —
NATALIE MORRIS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC)

Bills named: S. 64 (116th), S. 1416 (116th), H.R. 1499 (116th), H.R. 2375 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.